<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium acetate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium acetate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcium acetate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9184" href="/d/html/9184.html" rel="external">see "Calcium acetate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11300" href="/d/html/11300.html" rel="external">see "Calcium acetate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F144308"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Calphron [OTC];</li>
<li>Phoslyra [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1002723"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Calcium Salt</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812486"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose expressed in mg of <b>calcium acetate</b>. Phosphate binding capacity: Calcium acetate 1 g binds 45 mg of phosphorus (KDOQI 2005)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40c41a85-dc19-44f9-8062-454726438181">Control of hyperphosphatemia in end-stage renal failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Control of hyperphosphatemia in end-stage renal failure:</b> Limited data available; dose should be individualized: Children and Adolescents: Oral: Reported initial dose: 667 to 1,000 mg with each meal; titrate (every 2 to 4 weeks) to response and as serum calcium levels allow (Gulati 2010; Wallot 1996). <b>Note:</b> KDOQI guidelines recommend limiting the calcium provided from phosphate binders to 1,500 mg elemental calcium per day and total intake to 2,000 mg elemental calcium from all sources (KDOQI 2010)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729622"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F52729623"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F144311"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9184" href="/d/html/9184.html" rel="external">see "Calcium acetate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Calcium acetate 667 mg contains 169 mg <b>elemental </b>calcium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="260f20d5-597c-46c0-b39a-7bd210352f76">Hyperphosphatemia in chronic kidney disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperphosphatemia in chronic kidney disease, treatment: </b>
<b>Note: </b>Use in combination with dietary phosphate restriction (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: Initial:</b> 1,334 mg calcium acetate with each meal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage adjustment:</b> Increase or decrease dose (eg, by 667 mg per meal) at 2- or 3-week intervals as needed to obtain targeted serum phosphorus concentrations; usual dosage range: 1,334 to 2,001 mg calcium acetate with each meal (Quarles 2022; Kovesdy 2018; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do not exceed 6,003 mg/day calcium acetate (1,500 mg/day <b>elemental</b> calcium) and limit total <b>elemental</b> calcium intake from all sources (ie, dietary and phosphate binders) to ≤2,000 mg/day (K/DOQI 2003; Kovesdy 2018). Monitor serum calcium concentrations and consider non–calcium-containing phosphate binders if hypercalcemia develops; do not administer additional calcium supplements.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81863c66-ac4f-45ff-b638-ded564c6efe2">Dietary supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement (OTC): Oral: </b>1 to 3 tablets with meals (3 times daily) or as directed by health care provider.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991905"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: There are no specific dosage adjustments recommended; however, a positive calcium balance (calculated by subtracting total body calcium losses from total calcium inputs) has been associated with increased mortality in patients with chronic kidney disease (CKD) (KDIGO 2017). Daily <b>elemental </b>calcium intake (including dietary sources and calcium-based phosphate binders) recommendations in patients with CKD G3A through G5D (patients on hemodialysis, peritoneal dialysis) vary; one guideline recommends not exceeding 2,000 mg/day (K/DOQI 2003), but more recent short-term studies in nondialysis patients suggest limiting intake to 800 to 1,000 mg/day (Hill 2013; Hill Gallant 2017; Spiegel 2012). Decisions regarding calcium acetate use and dose must be individualized to the patient, and hypercalcemia should be avoided (KDIGO 2017).</p></div>
<div class="block doha drugH1Div" id="F50989142"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F144285"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (oral solution)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Postmarketing and/or case reports: Dizziness, edema, pruritus, weakness</p></div>
<div class="block coi drugH1Div" id="F144299"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypercalcemia.</p></div>
<div class="block war drugH1Div" id="F144282"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Mild to severe hypercalcemia may occur; decrease calcium acetate dose or temporarily discontinue, depending on severity of hypercalcemia; in addition, decrease or discontinue any concomitant vitamin D therapy. Chronic hypercalcemia may result in generalized vascular and soft tissue calcification, exacerbate nephrolithiasis, and has been associated with increased mortality in adults with chronic kidney disease (CKD) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Use with caution in patients who may be at risk of cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic kidney disease: In CKD patients receiving phosphate-lowering treatment, consider using non-calcium-based phosphate-lowering agents (eg, sevelamer, lanthanum) as an alternative to calcium-based phosphate-lowering agents (eg, calcium acetate, calcium carbonate) or restricting the dose of the calcium-based phosphate-lowering agents (Allison 2013; KDIGO 2017). A meta-analysis observed a trend toward a decrease in all-cause mortality in CKD patients receiving non-calcium-based phosphate-lowering agents compared with those receiving calcium-based phosphate-lowering agents (Jamal 2013); however, further research is needed to identify causes of mortality and fully assess safety of long-term use based on phosphate-lowering agent type.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in patients with hypoparathyroidism who are receiving high doses of vitamin D.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Digitalis: Use with caution in digitalized patients; hypercalcemia may precipitate cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Maltitol: Oral solution may contain maltitol (a sugar substitute) which may cause a laxative effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878361"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP, 1997; Shehab, 2009).</p></div>
<div class="block dosfc drugH1Div" id="F21879437"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Calcium acetate is approximately 25% elemental calcium</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium acetate 667 mg =  elemental calcium 169 mg = calcium 8.45 mEq = calcium 4.23 mmol</p></div>
<div class="block foc drugH1Div" id="F144293"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 667 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Phoslyra: 667 mg/5 mL (473 mL [DSC]) [contains methylparaben, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calphron: 667 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 667 mg, 668 mg</p></div>
<div class="block geq drugH1Div" id="F144278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F144302"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Calcium Acetate (Phos Binder) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">667 mg (per each): $0.17 - $1.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Calcium Acetate (Phos Binder) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">667 mg (per each): $0.15 - $1.16</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Calcium Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">667 mg (per each): $1.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">668 (169 Ca) mg (per each): $0.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Calphron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">667 mg (per each): $0.17</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53565608"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected <b>total</b> serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 – patient's albumin) x 0.8] + patient's measured total calcium</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">Elemental Calcium Content of Calcium Salts</caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Calcium Salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental Calcium</p>
<p style="text-indent:0em;">(mg/1 g of salt form) </p></th>
<th align="center">
<p style="text-indent:0em;">Calcium</p>
<p style="text-indent:0em;">(mEq/g) </p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium acetate </p></td>
<td align="center">
<p style="text-indent:0em;">253</p></td>
<td align="center">
<p style="text-indent:0em;">12.7</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium carbonate</p></td>
<td align="center">
<p style="text-indent:0em;">400</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium chloride</p></td>
<td align="center">
<p style="text-indent:0em;">273</p></td>
<td align="center">
<p style="text-indent:0em;">13.6</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium citrate</p></td>
<td align="center">
<p style="text-indent:0em;">211</p></td>
<td align="center">
<p style="text-indent:0em;">10.5</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium glubionate</p></td>
<td align="center">
<p style="text-indent:0em;">63.8</p></td>
<td align="center">
<p style="text-indent:0em;">3.2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">93</p></td>
<td align="center">
<p style="text-indent:0em;">4.65</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium lactate</p></td>
<td align="center">
<p style="text-indent:0em;">130</p></td>
<td align="center">
<p style="text-indent:0em;">6.5</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium phosphate (tribasic)</p></td>
<td align="center">
<p style="text-indent:0em;">390</p></td>
<td align="center">
<p style="text-indent:0em;">19.3</p></td></tr></tbody></table>
<p style="text-indent:0em;">Chronic kidney disease (CKD) (KDIGO 2013; KDOQI 2002): Children ≥2 years, Adolescents, and Adults: GFR &lt;60 mL/minute/1.73 m<sup>2</sup> or kidney damage for &gt;3 months; stages of CKD are described below:</p>
<p style="text-indent:-2em;margin-left:4em;">CKD Stage 1: Kidney damage with normal or increased GFR; GFR &gt;90 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">CKD Stage 2: Kidney damage with mild decrease in GFR; GFR 60 to 89 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">CKD Stage 3: Moderate decrease in GFR; GFR 30 to 59 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">CKD Stage 4: Severe decrease in GFR; GFR 15 to 29 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:4em;">CKD Stage 5: Kidney failure; GFR &lt;15 mL/minute/1.73 m<sup>2</sup> or dialysis </p></div>
<div class="block admp drugH1Div" id="F52612342"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with plenty of fluids with meals to optimize effectiveness</p></div>
<div class="block adm drugH1Div" id="F144296"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer with meals. Do not chew tablets.</p></div>
<div class="block sts drugH1Div" id="F54993111"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53565790"><span class="drugH1">Use</span>
<p style="text-indent:0em;text-align:justify;display:inline">Treatment of hyperphosphatemia in end-stage renal failure (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F144331"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PhosLo may be confused with Phos-Flur, ProSom</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298930"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F144287"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts.  Management: Separate administration of alpha-lipoic acid from that of any calcium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral calcium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the adverse/toxic effect of Calcium Acetate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estramustine: Calcium Salts may decrease the absorption of Estramustine.  Management: Administer estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. If coadministered with calcium salts, monitor for decreased estramustine therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Calcium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents.  Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F12780466"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Foods that contain maltitol may have an additive laxative effect with the oral solution formulation (contains maltitol). </p></div>
<div class="block dic drugH1Div" id="F144303"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Oral dosage forms must be administered with meals to be effective.</p></div>
<div class="block pri drugH1Div" id="F12769413"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Calcium crosses the placenta (IOM 2011).</p>
<p style="text-indent:0em;margin-top:2em;">The amount of calcium reaching the fetus is determined by maternal physiological changes. Intestinal absorption of calcium increases during pregnancy (IOM 2011). Administration of calcium acetate to pregnant patients with kidney failure on dialysis is not expected to cause adverse maternal or fetal outcomes; however, untreated maternal kidney failure and hypercalcemia may lead to pregnancy complications. Maternal calcium concentrations should be monitored and maintained within normal limits.</p></div>
<div class="block mopp drugH1Div" id="F53565777"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium (twice weekly during initial dose adjustments), serum phosphorus; serum calcium-phosphorus product; intact parathyroid hormone (iPTH)</p></div>
<div class="block rerp drugH1Div" id="F53565607"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Corrected total serum calcium: Children, Adolescents, and Adults: CKD stages 2 to 5D: Maintain normal ranges; preferably on the lower end for stage 5 (KDIGO 2009; KDOQI 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Phosphorus (KDIGO 2009): </p>
<p style="text-indent:-2em;margin-left:4em;">CKD stages 3 to 5: Maintain normal ranges</p>
<p style="text-indent:-2em;margin-left:4em;">CKD stage 5D: Lower elevated phosphorus levels toward the normal range</p></div>
<div class="block pha drugH1Div" id="F144281"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Combines with dietary phosphate to form insoluble calcium phosphate which is excreted in feces</p></div>
<div class="block phk drugH1Div" id="F144298"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 30% to 40%; requires vitamin D; minimal unless chronic, high doses are given; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily feces (as unabsorbed calcium); urine (20%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5549431"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Qelax P | Royen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calciumacetat Medice | Phos ex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nephrex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Hypophos | Remophos</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Phoslo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acetaphos | Calcium Acetat | Calcium acetat phosphatbinder | Renacet</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Phoslo</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ace-cal | Si lin tuo</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kelafox | Royen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calcet | Calciumacetat | Calciumacetat Nefro | Calciumacetat prorenal nem | Phos ex | Phosphosorb | Renacet</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Phos ex | Phosphosorb</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Marcal | Prorenal plus | Rendose</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acetato de calcio renacare | Royen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Phos ex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Phosphosorb</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Everose | Phosex | Phoslo | Renacet</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Phosphosorb</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calcetat</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Calcium Acetat | Phosex | Renacet</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Calsicon | Hypophos | Lanum | Phosbi | Phosforid | Phostat | Renaphos | Septacal | Zerofos</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Phoslo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Caltate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caloin | Calsuit | Nephro | Phosbine | Phoslo | Phosphine | Phospo | Phostrol | Poshuin | Pospo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Phospholow</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcium acetate Nephro | Calciumacetat | Calciumacetat Nefro | Phosphosorb</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Calciumacetate Nefro | Phosphosorb</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calciumacetat Nefro</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Calciumacetaat-Nefro | Phosex | Phoslo</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Phos ex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Calcimark | Lophos | Phoslo | Prayphos | Urophos</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Calcifos</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eliphos | Phoslo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Phosphosorb</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Phos ex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Calcetate</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anti fosfat ca | Fix at | Fosfat ex | Phos No | Phos out</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ace-cal | Ca P | Calacet | Calowlin | Caphos | Delincal | Phos Cal | Phosunk | Proca | Procal | Supcal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Royen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Phosphosorb</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23917795">
<a name="23917795"></a>Allison SJ. Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders: effect on mortality in patients with CKD. <i>Nat Rev Nephrol</i>. 2013;9(9):491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/23917795/pubmed" id="23917795" target="_blank">23917795</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Calcium Acetate Capsules (phosphate binder calcium acetate) [prescribing information]. Columbus, OH: American Health Packaging; January 2021.</div>
</li>
<li>
<div class="reference">
                  Calcium Acetate Gelcaps (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; April 2018.</div>
</li>
<li>
<div class="reference">
                  Calphron (calcium acetate) [prescribing information]. Shawnee, KS: Nephro-Tech Inc; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20020207">
<a name="20020207"></a>Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. <i>Int Urol Nephrol</i>. 2010;42(4):1055-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/20020207/pubmed" id="20020207" target="_blank">20020207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28474258">
<a name="28474258"></a>Hill Gallant KM, Spiegel DM. Calcium balance in chronic kidney disease. <i>Curr Osteoporos Rep</i>. 2017;15(3):214-221. doi:10.1007/s11914-017-0368-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/28474258/pubmed" id="28474258" target="_blank">28474258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23254903">
<a name="23254903"></a>Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. <i>Kidney Int</i>. 2013;83(5):959-966. doi:10.1038/ki.2012.403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/23254903/pubmed" id="23254903" target="_blank">23254903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23870817">
<a name="23870817"></a>Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. <i>Lancet</i>. 2013;382(9900):1268-1277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/23870817/pubmed" id="23870817" target="_blank">23870817</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). <i>Kidney Int</i>. 2017;7(suppl 1):1-59. doi:10.1016/j.kisu.2017.04.001</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19644521">
<a name="19644521"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl</i>. 2009;(113):S1-S130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/19644521/pubmed" id="19644521" target="_blank">19644521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29989014">
<a name="29989014"></a>Kovesdy CP, Lu JL, Wall BM, et al. Changes with lanthanum carbonate, calcium acetate, and phosphorus restriction in CKD: a randomized controlled trial. <i>Kidney Int Rep</i>. 2018;3(4):897-904. doi:10.1016/j.ekir.2018.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/29989014/pubmed" id="29989014" target="_blank">29989014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14520607">
<a name="14520607"></a>National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2003;42(4)(suppl 3):S1-S201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/14520607/pubmed" id="14520607" target="_blank">14520607</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. <i>Am J Kidney Dis</i>. 2005;46:S1-S122.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11904577">
<a name="11904577"></a>National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. <i>Am J Kidney Dis</i>. 2002;39(2)(suppl 1):S1-S266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/11904577/pubmed" id="11904577" target="_blank">11904577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20363541">
<a name="20363541"></a>National Kidney Foundation. K/DOQI US commentary of the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD – mineral and bone disorder (CKD-MBD). <i>Am J Kidney Dis</i>. 2010;55(5):773-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/20363541/pubmed" id="20363541" target="_blank">20363541</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Phoslyra (calcium acetate) [prescribing information]. Waltham, MA: Fresenius Medical Care North America; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berkoben.1">
<a name="Berkoben.1"></a>Quarles LD. Management of hyperphosphatemia in adults with chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22297674">
<a name="22297674"></a>Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. <i>Kidney Int</i>. 2012;81(11):1116-1122. doi:10.1038/ki.2011.490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/22297674/pubmed" id="22297674" target="_blank">22297674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8897570">
<a name="8897570"></a>Wallot M, Bonzel KE, Winter A, Geörger B, Lettgen B, Bald M. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. <i>Pediatr Nephrol</i>. 1996;10(5):625-630.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/8897570/pubmed" id="8897570" target="_blank">8897570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-acetate-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13085 Version 357.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
